OA12053A - HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor. - Google Patents

HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor. Download PDF

Info

Publication number: OA12053A
Authority: OA; OAPI
Prior art keywords: compound; daims; substance; composition; retrovirus
Prior art date: 1999-10-06

Application number

OA1200200096A

Other languages

English (en)

Inventor

Piet Tom Bert Paul Wigerinck

Guangyang Wang

Michael Eissenstat

John W Erickson

Original Assignee

Tibotec Pharm Ltd

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-06

Filing date

2000-10-06

Publication date

2006-05-02

2000-10-06 Application filed by Tibotec Pharm Ltd, Us Gov Health & Human Serv filed Critical Tibotec Pharm Ltd

2006-05-02 Publication of OA12053A publication Critical patent/OA12053A/en

Links

230000001177 retroviral effect Effects 0.000 title claims description 5
239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract description 11
-1 1,3-benzodioxol-5-ylsulfonyl Chemical group 0.000 title description 17
229940124158 Protease/peptidase inhibitor Drugs 0.000 title description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 26
241001430294 unidentified retrovirus Species 0.000 claims abstract description 13
241000124008 Mammalia Species 0.000 claims abstract description 10
108091005804 Peptidases Proteins 0.000 claims abstract description 10
230000002401 inhibitory effect Effects 0.000 claims abstract description 10
239000004365 Protease Substances 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
208000015181 infectious disease Diseases 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
201000010099 disease Diseases 0.000 claims abstract 3
208000005074 Retroviridae Infections Diseases 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 98
239000000203 mixture Substances 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 17
239000000126 substance Substances 0.000 claims description 15
241000725303 Human immunodeficiency virus Species 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 10
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 8
239000000651 prodrug Substances 0.000 claims description 8
229940002612 prodrug Drugs 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 5
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract description 8
OHYSGENGXKDFOG-UHFFFAOYSA-N 1,3-benzodioxole-2-sulfonamide;oxolane Chemical class C1CCOC1.C1CCOC1.C1=CC=C2OC(S(=O)(=O)N)OC2=C1 OHYSGENGXKDFOG-UHFFFAOYSA-N 0.000 abstract description 2
102000035195 Peptidases Human genes 0.000 abstract 2
230000029812 viral genome replication Effects 0.000 abstract 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 15
239000003112 inhibitor Substances 0.000 description 15
102200089571 rs104893827 Human genes 0.000 description 14
102220162518 rs755579963 Human genes 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
230000000694 effects Effects 0.000 description 12
239000002904 solvent Substances 0.000 description 11
102220351589 c.28C>A Human genes 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 9
102220288746 rs140563222 Human genes 0.000 description 9
239000000243 solution Substances 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
241000700605 Viruses Species 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
229920000858 Cyclodextrin Polymers 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
102220080214 rs149830675 Human genes 0.000 description 7
102220072394 rs200671745 Human genes 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 6
229960001830 amprenavir Drugs 0.000 description 6
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
229960000311 ritonavir Drugs 0.000 description 6
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 6
229960001852 saquinavir Drugs 0.000 description 6
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 6
239000007962 solid dispersion Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
150000001414 amino alcohols Chemical class 0.000 description 5
230000036436 anti-hiv Effects 0.000 description 5
229960001936 indinavir Drugs 0.000 description 5
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 4
206010001513 AIDS related complex Diseases 0.000 description 4
102000012404 Orosomucoid Human genes 0.000 description 4
108010061952 Orosomucoid Proteins 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
102200027218 c.217G>A Human genes 0.000 description 4
229940126543 compound 14 Drugs 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102220278104 rs1554096640 Human genes 0.000 description 4
102220057902 rs730881670 Human genes 0.000 description 4
102220097967 rs876660873 Human genes 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102220470514 Proteasome subunit beta type-3_V82A_mutation Human genes 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000011324 bead Substances 0.000 description 3
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
239000003607 modifier Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
229960000884 nelfinavir Drugs 0.000 description 3
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000006104 solid solution Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229930184489 Iodoether Natural products 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
244000126002 Ziziphus vulgaris Species 0.000 description 2
235000008529 Ziziphus vulgaris Nutrition 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940124522 antiretrovirals Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000036983 biotransformation Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000004030 hiv protease inhibitor Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000011534 incubation Methods 0.000 description 2
VSHDHKDWBUMJIJ-UHFFFAOYSA-N iodo hypoiodite Chemical compound IOI VSHDHKDWBUMJIJ-UHFFFAOYSA-N 0.000 description 2
BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
102220274636 rs144712084 Human genes 0.000 description 2
102220067568 rs202141764 Human genes 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
IXZYCIFRVZKVRJ-RKKDRKJOSA-N (2s)-n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)[C@@H](NC(=O)CNCC=1C=C(F)C=CC=1)C(C)(C)C)C1=CC=CC=C1 IXZYCIFRVZKVRJ-RKKDRKJOSA-N 0.000 description 1
RCDXYCHYMULCDZ-HCWXCVPCSA-N (3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-ol Chemical compound O1CC[C@H]2[C@@H](O)CO[C@H]21 RCDXYCHYMULCDZ-HCWXCVPCSA-N 0.000 description 1
HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 description 1
JJWJSIAJLBEMEN-ZDUSSCGKSA-N (4s)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)#CC1CC1 JJWJSIAJLBEMEN-ZDUSSCGKSA-N 0.000 description 1
UXDWYQAXEGVSPS-GFUIURDCSA-N (4s)-6-chloro-4-[(e)-2-cyclopropylethenyl]-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one Chemical compound C(/[C@]1(C2=CC(Cl)=CC=C2NC(=O)N1)C(F)(F)F)=C\C1CC1 UXDWYQAXEGVSPS-GFUIURDCSA-N 0.000 description 1
BEMROAADXJFLBI-UHFFFAOYSA-N 1-(cyclopent-3-en-1-ylmethyl)-6-(3,5-dimethylbenzoyl)-5-ethylpyrimidine-2,4-dione Chemical compound C1C=CCC1CN1C(=O)NC(=O)C(CC)=C1C(=O)C1=CC(C)=CC(C)=C1 BEMROAADXJFLBI-UHFFFAOYSA-N 0.000 description 1
JKTOKCJLZBURKJ-UHFFFAOYSA-N 1-hydroxy-2-(sulfamoylamino)ethane Chemical compound NS(=O)(=O)NCCO JKTOKCJLZBURKJ-UHFFFAOYSA-N 0.000 description 1
ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical class COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
YZHIXLCGPOTQNB-UHFFFAOYSA-N 2-methyl-furan-3-carbothioic acid [4-chloro-3-(3-methyl-but-2-enyloxy)-phenyl]-amide Chemical compound C1=C(Cl)C(OCC=C(C)C)=CC(NC(=S)C2=C(OC=C2)C)=C1 YZHIXLCGPOTQNB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
RRZVGDGTWNQAPW-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile Chemical compound C1=NN(C)C=C1CCN1C(C=2C=CC(=CC=2)C#N)=C(C2=CN(C)N=C2)N=C1 RRZVGDGTWNQAPW-UHFFFAOYSA-N 0.000 description 1
ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 description 1
OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
108010019625 Atazanavir Sulfate Proteins 0.000 description 1
CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
NIDRYBLTWYFCFV-IUUKEHGRSA-N Calanolide A Natural products C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-IUUKEHGRSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229940121672 Glycosylation inhibitor Drugs 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
229940124821 NNRTIs Drugs 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
229960004748 abacavir Drugs 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003277 atazanavir Drugs 0.000 description 1
AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229950009494 bropirimine Drugs 0.000 description 1
NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 description 1
YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
229950008230 capravirine Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960002049 etravirine Drugs 0.000 description 1
PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940124524 integrase inhibitor Drugs 0.000 description 1
239000002850 integrase inhibitor Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229960004525 lopinavir Drugs 0.000 description 1
CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
229950006243 loviride Drugs 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
229960003086 naltrexone Drugs 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
229960002169 plerixafor Drugs 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
238000007154 radical cyclization reaction Methods 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
102200042996 rs1057521927 Human genes 0.000 description 1
102200156953 rs121964883 Human genes 0.000 description 1
102220246449 rs143520192 Human genes 0.000 description 1
102220018603 rs397517057 Human genes 0.000 description 1
102200002453 rs55758736 Human genes 0.000 description 1
102220053718 rs573489857 Human genes 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000000565 sulfonamide group Chemical group 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
229960000838 tipranavir Drugs 0.000 description 1
NZPXPXAGXYTROM-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(O)=C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)C1)CC1=CC=CC=C1 NZPXPXAGXYTROM-FYBSXPHGSA-N 0.000 description 1
229950011282 tivirapine Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

OA1200200096A 1999-10-06 2000-10-06 HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor. OA12053A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15785099P	1999-10-06	1999-10-06

Publications (1)

Publication Number	Publication Date
OA12053A true OA12053A (en)	2006-05-02

Family

ID=22565540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200096A OA12053A (en)	1999-10-06	2000-10-06	HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.

Country Status (25)

Country	Link
US (2)	US6649651B1 (da)
EP (1)	EP1222192B8 (da)
JP (1)	JP4951179B2 (da)
KR (1)	KR100792391B1 (da)
CN (1)	CN1191256C (da)
AP (1)	AP1459A (da)
AT (1)	ATE398623T1 (da)
AU (1)	AU781656B2 (da)
BR (1)	BR0014602A (da)
CA (1)	CA2386850C (da)
CZ (1)	CZ300031B6 (da)
DE (1)	DE60039244D1 (da)
DK (1)	DK1222192T3 (da)
ES (1)	ES2307533T3 (da)
HU (1)	HU228938B1 (da)
IL (2)	IL149005A0 (da)
MX (1)	MXPA02003607A (da)
NO (1)	NO327996B1 (da)
NZ (1)	NZ518580A (da)
OA (1)	OA12053A (da)
PL (1)	PL204924B1 (da)
RU (1)	RU2247123C2 (da)
SK (1)	SK287153B6 (da)
WO (1)	WO2001025240A1 (da)
ZA (1)	ZA200202655B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1222192B8 (en) *	1999-10-06	2008-10-01	Tibotec Pharmaceuticals Ltd.	Hexahydrofuro¬2,3-b furan-3-yl-n- 3-¬(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino -1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor
AR035819A1 (es) *	2001-04-09	2004-07-14	Tibotec Pharm Ltd	2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos
EA010883B1 (ru) *	2001-09-10	2008-12-30	Тиботек Фармасьютикалз Лтд.	Способ получения гексагидрофуро[2,3-в]фуран-3-ола
AU2003202914A1 (en) *	2002-01-07	2003-07-24	Sequoia Pharmaceuticals	Broad spectrum inhibitors
US7285566B2 (en) *	2002-01-07	2007-10-23	Erickson John W	Resistance-repellent retroviral protease inhibitors
US7157489B2 (en) *	2002-03-12	2007-01-02	The Board Of Trustees Of The University Of Illinois	HIV protease inhibitors
KR101019648B1 (ko)	2002-05-17	2011-03-07	티보텍 파마슈티컬즈	광범위 스펙트럼의 치환된 벤즈이속사졸 설폰아미드ｈｉｖ 프로테아제 저해제
KR101327772B1 (ko) *	2002-08-02	2013-11-11	얀센 알 앤드 디 아일랜드	광범위 2-아미노-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제
WO2004060895A1 (ja)	2002-12-27	2004-07-22	Sumitomo Chemical Company, Limited	ヘキサヒドロフロフラノール誘導体の製造方法、その中間体及びその製造方法
EP1732891A4 (en) *	2004-03-11	2009-05-06	Sequoia Pharmaceuticals Inc	RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
TWI383975B (zh)	2004-03-31	2013-02-01	悌柏泰克醫藥有限公司	製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
KR100698291B1 (ko) *	2004-12-29	2007-03-22	엘지전자 주식회사	조명계
RU2421459C2 (ru)	2005-02-25	2011-06-20	Тиботек Фармасьютикалз Лтд.	Синтез предшественника ингибитора протеазы
FR2888849B1 (fr) *	2005-07-19	2007-10-05	Pierre Fabre Medicament Sa	Procede de preparation de la 4b-amino-4'-demethyl-4-desoxypodophyllotoxine
SG183007A1 (en)	2006-07-07	2012-08-30	Gilead Sciences Inc	Modulators of pharmacokinetic properties of therapeutics
US20080070910A1 (en) *	2006-07-24	2008-03-20	Desai Manoj C	Therapeutic compounds and methods
MX2009004957A (es)	2006-11-09	2009-05-19	Tibotec Pharm Ltd	Metodos para la preparacion de hexahidrofuro[2,3-b]furan-3-ol.
US9808527B2 (en)	2006-11-21	2017-11-07	Purdue Research Foundation	Methods and compositions for treating HIV infections
PL3150586T3 (pl)	2007-02-23	2020-06-01	Gilead Sciences, Inc.	Modulatory farmakokinetycznych właściwości środków terapeutycznych
US7981929B2 (en) *	2007-03-16	2011-07-19	Sequoia Pharmaceuticals, Inc.	Benzofuran derived HIV protease inhibitors
EP2170851B1 (en)	2007-07-06	2013-09-04	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
PT2231628E (pt)	2008-01-04	2015-12-29	Gilead Sciences Inc	Inibidores de citocromo p450
WO2009091941A1 (en)	2008-01-17	2009-07-23	Purdue Research Foundation	Small molecule inhibitors of hiv proteases
US8791135B2 (en)	2008-07-01	2014-07-29	Purdue Research Foundation	Nonpeptide HIV-1 protease inhibitors
US8501961B2 (en) *	2008-07-09	2013-08-06	Purdue Research Foundation	HIV protease inhibitors and methods for using
UA112155C2 (uk)	2009-12-21	2016-08-10	ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі	Розкладаний видалюваний імплантат для безперервного вивільнення активної сполуки
DK2643326T3 (da)	2010-11-23	2017-01-09	Mylan Laboratories Ltd	Fremgangsmåde til fremstilling af (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol
CN104520262A (zh) *	2012-08-09	2015-04-15	住友化学株式会社	六氢呋喃并呋喃醇衍生物的制造方法
CN103664976B (zh) *	2013-12-12	2015-11-04	惠州市莱佛士制药技术有限公司	一种顺式六氢呋喃并[2,3-b]呋喃-3-醇的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994004491A1 (en) *	1992-08-25	1994-03-03	G.D. Searle & Co.	N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
ATE218541T1 (de) *	1992-08-25	2002-06-15	Searle & Co	Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
IS2334B (is) *	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) *	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
EP0715618B1 (en)	1993-08-24	1998-12-16	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
US5705500A (en) *	1995-03-10	1998-01-06	G.D. Searle & Co.	Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) *	1995-04-19	1997-11-25	Vertex Pharmaceuticals Incorporated	Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
PT2336134T (pt)	1998-06-23	2016-10-19	The Board Of Trustees Of The Univ Of Illionis	Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
WO1999067254A2 (en) *	1998-06-23	1999-12-29	The United States Of America Represented By The Secretary, Department Of Health And Human Services	Multi-drug resistant retroviral protease inhibitors and use thereof
GB9815567D0 (en) *	1998-07-18	1998-09-16	Glaxo Group Ltd	Antiviral compound
EP1222192B8 (en) *	1999-10-06	2008-10-01	Tibotec Pharmaceuticals Ltd.	Hexahydrofuro¬2,3-b furan-3-yl-n- 3-¬(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino -1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor

2000
- 2000-10-06 EP EP00966144A patent/EP1222192B8/en not_active Expired - Lifetime
- 2000-10-06 WO PCT/EP2000/009917 patent/WO2001025240A1/en not_active Ceased
- 2000-10-06 IL IL14900500A patent/IL149005A0/xx active IP Right Grant
- 2000-10-06 PL PL354351A patent/PL204924B1/pl unknown
- 2000-10-06 MX MXPA02003607A patent/MXPA02003607A/es active IP Right Grant
- 2000-10-06 DK DK00966144T patent/DK1222192T3/da active
- 2000-10-06 BR BR0014602-1A patent/BR0014602A/pt not_active Application Discontinuation
- 2000-10-06 AP APAP/P/2002/002472A patent/AP1459A/en active
- 2000-10-06 CZ CZ20021419A patent/CZ300031B6/cs not_active IP Right Cessation
- 2000-10-06 OA OA1200200096A patent/OA12053A/en unknown
- 2000-10-06 AT AT00966144T patent/ATE398623T1/de not_active IP Right Cessation
- 2000-10-06 DE DE60039244T patent/DE60039244D1/de not_active Expired - Lifetime
- 2000-10-06 CN CNB008165874A patent/CN1191256C/zh not_active Expired - Lifetime
- 2000-10-06 SK SK570-2002A patent/SK287153B6/sk not_active IP Right Cessation
- 2000-10-06 JP JP2001528184A patent/JP4951179B2/ja not_active Expired - Lifetime
- 2000-10-06 CA CA2386850A patent/CA2386850C/en not_active Expired - Lifetime
- 2000-10-06 ES ES00966144T patent/ES2307533T3/es not_active Expired - Lifetime
- 2000-10-06 KR KR1020027004284A patent/KR100792391B1/ko not_active Expired - Lifetime
- 2000-10-06 HU HU0203130A patent/HU228938B1/hu unknown
- 2000-10-06 US US10/089,991 patent/US6649651B1/en not_active Expired - Lifetime
- 2000-10-06 NZ NZ518580A patent/NZ518580A/en not_active IP Right Cessation
- 2000-10-06 AU AU76638/00A patent/AU781656B2/en not_active Expired
- 2000-10-06 RU RU2002111657/04A patent/RU2247123C2/ru active
2002
- 2002-04-04 IL IL149005A patent/IL149005A/en unknown
- 2002-04-04 ZA ZA200202655A patent/ZA200202655B/xx unknown
- 2002-04-04 NO NO20021598A patent/NO327996B1/no not_active IP Right Cessation
2003
- 2003-06-25 US US10/606,342 patent/US7157495B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2003511383A (ja)	2003-03-25
PL354351A1 (en)	2004-01-12
US20050261364A1 (en)	2005-11-24
WO2001025240A1 (en)	2001-04-12
AP1459A (en)	2005-08-22
KR20020067503A (ko)	2002-08-22
ATE398623T1 (de)	2008-07-15
IL149005A (en)	2006-12-31
HK1054746A1 (en)	2003-12-12
DE60039244D1 (de)	2008-07-31
CZ20021419A3 (cs)	2002-10-16
ZA200202655B (en)	2003-09-23
EP1222192B8 (en)	2008-10-01
HUP0203130A3 (en)	2005-01-28
PL204924B1 (pl)	2010-02-26
CA2386850C (en)	2010-03-30
CA2386850A1 (en)	2001-04-12
NO20021598D0 (no)	2002-04-04
ES2307533T3 (es)	2008-12-01
JP4951179B2 (ja)	2012-06-13
EP1222192A1 (en)	2002-07-17
CN1407987A (zh)	2003-04-02
NO327996B1 (no)	2009-11-02
BR0014602A (pt)	2002-06-11
AU781656B2 (en)	2005-06-02
CN1191256C (zh)	2005-03-02
CZ300031B6 (cs)	2009-01-14
MXPA02003607A (es)	2003-07-28
AU7663800A (en)	2001-05-10
KR100792391B1 (ko)	2008-01-08
HUP0203130A2 (hu)	2003-01-28
SK5702002A3 (en)	2003-01-09
SK287153B6 (sk)	2010-01-07
NZ518580A (en)	2004-01-30
DK1222192T3 (da)	2008-10-20
RU2247123C2 (ru)	2005-02-27
AP2002002472A0 (en)	2002-06-30
HU228938B1 (hu)	2013-06-28
US6649651B1 (en)	2003-11-18
US7157495B2 (en)	2007-01-02
NO20021598L (no)	2002-05-29
IL149005A0 (en)	2002-11-10
EP1222192B1 (en)	2008-06-18

Publication	Publication Date	Title
OA12053A (en)	2006-05-02	HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.
AU2003262561B2 (en)	2008-10-16	Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
KR100872029B1 (ko)	2008-12-05	광범위 2-(치환된-아미노)-벤즈옥사졸 설폰아미드 ｈｉｖ프로테아제 저해제
EP1960404B1 (en)	2015-06-17	Substituted aminophenylsulfonamide compounds as hiv protease inhibitors
KR20050013549A (ko)	2005-02-04	광범위 스펙트럼의 치환된 벤즈이속사졸 설폰아미드ｈｉｖ 프로테아제 저해제
KR101327772B1 (ko)	2013-11-11	광범위 2-아미노-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제
US7803836B2 (en)	2010-09-28	Aminophenylsulfonamide derivatives as HIV protease inhibitor
HK1054746B (en)	2005-12-09	Hexahydrofuro'2,3-b!furan-3-yl-n- {3'(1,3-benzodioxol -5- ylsulfonyl) (isobutyl) amino! -1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor